Stone and Laser Therapies Post-Market Study (SALT)
Active, not recruiting · NCT06982235
Conditions: Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary, Urinary Tract Procedure
At a glance
- Research payments reported, 2025
- $20,906
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 238
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- Ureteroscope system (device), Laser system (device)
- Dates
- Started 2025-06-30; completion 2029-02
- Results posted
- Not yet
The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary tract procedure (e.g., transurethral or percutaneous access routes) or benign prostatic hyperplasia (BPH) treatment.
From ClinicalTrials.gov, last updated 2026-10-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $20,906 in research payments for this study in 2025 (2 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Indiana University $12,726
- University of Miami $8,180
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.